ADARx director reports 7.13M shares tied to Series A
ADARx Pharmaceuticals, Inc. director Erez Chimovits reported indirect positions in four preferred-stock series held directly by OrbiMed Israel Partners II, L.P.
Rhea-AI Filing Summary
ADARx Pharmaceuticals, Inc. director Erez Chimovits reported indirect positions in four preferred-stock series held directly by OrbiMed Israel Partners II, L.P. The reported common-share amounts, giving effect to conversion, are 7,127,019 for Series A, 1,333,975 for Series B, 513,067 for Series B-1 and 256,448 for Series C. Each preferred share automatically converts into common stock on a 1-for-1.1717 basis upon the issuer’s IPO closing, without further consideration. OrbiMed Advisors Israel II Limited exercises voting and investment power through a committee comprising Chimovits, Carl L. Gordon and David P. Bonita; all three disclaim beneficial ownership except to the extent of any pecuniary interest.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Chimovits Erez
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Preferred Stock F1, F2, F3 | -- | -- | -- |
| holding | Series B Preferred Stock F1, F2, F3 | -- | -- | -- |
| holding | Series B-1 Preferred Stock F1, F2, F3 | -- | -- | -- |
| holding | Series C Preferred Stock F1, F2, F3 | -- | -- | -- |
Holdings After Transaction:
Series A Preferred Stock — 7,127,019 contracts (Indirect, See footnotes);
Series B Preferred Stock — 1,333,975 contracts (Indirect, See footnotes);
Series B-1 Preferred Stock — 513,067 contracts (Indirect, See footnotes);
Series C Preferred Stock — 256,448 contracts (Indirect, See footnotes)
Footnotes (3)
- F1. Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") will automatically convert on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
- F2. These securities are held directly by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II. OrbiMed Advisors Israel II Limited ("Advisors Israel") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II.
- F3. Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Series A Preferred Stock reported common-share amount: 7,127,019 shares
Series B Preferred Stock reported common-share amount: 1,333,975 shares
Series B-1 Preferred Stock reported common-share amount: 513,067 shares
+2 more
5 metrics
Series A Preferred Stock reported common-share amount
7,127,019 shares
Reported holding entry dated September 24, 2026; share number gives effect to conversion.
Series B Preferred Stock reported common-share amount
1,333,975 shares
Reported holding entry dated September 24, 2026; share number gives effect to conversion.
Series B-1 Preferred Stock reported common-share amount
513,067 shares
Reported holding entry dated September 24, 2026; share number gives effect to conversion.
Series C Preferred Stock reported common-share amount
256,448 shares
Reported holding entry dated September 24, 2026; share number gives effect to conversion.
Preferred Stock conversion ratio
1-for-1.1717
Conversion into Common Stock upon closing of the issuer’s IPO.
Key Terms
beneficial ownership, pecuniary interest, general partner, 1-for-1.1717 basis
4 terms
beneficial ownership regulatory
"may be deemed to have beneficial ownership over such securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest regulatory
"except to the extent of its pecuniary interest therein, if any"
general partner regulatory
"Israel GP is the general partner of OIP II"
A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.
1-for-1.1717 basis technical
"convert on a 1-for-1.1717 basis into shares of Common Stock"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ADARx preferred-stock holdings did director Erez Chimovits report?
OrbiMed Israel Partners II, L.P. directly holds the preferred stock; the reported common-share amounts, giving effect to conversion, are Series A 7,127,019, Series B 1,333,975, Series B-1 513,067 and Series C 256,448.
AI-generated analysis. How Rhea-AI works. Not financial advice.
